Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Cipla's average EBITDA Per Share Growth Rate was -28.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cipla was 24.60% per year. The lowest was 1.80% per year. And the median was 13.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Cipla 5-Year EBITDA Growth Rate Related Terms
LUX:CIPLA vs ZTS: 5-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cipla's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 11.10% mean?
Cipla (LUX:CIPLA) has a 5-Year EBITDA Growth Rate of 11.10% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Cipla and its competitors.
Is Cipla's 5-Year EBITDA Growth Rate too high?
Cipla's current 5-Year EBITDA Growth Rate is 11.10%. Overall, Cipla has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's 5-Year EBITDA Growth Rate compare to ZTS?
Cipla's 5-Year EBITDA Growth Rate of 11.10% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Cipla and its competitors. Cipla's current 5-Year EBITDA Growth Rate is 11.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current 5-Year EBITDA Growth Rate of 11.10%. The stock's GF Value™ is $19.19, compared to a current price of $18.10 — trading 5.7% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 11.10%. Cipla's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current 5-Year EBITDA Growth Rate is 11.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 5.7% below its estimated GF Value™ of $19.19.
Key valuation signals for LUX:CIPLA:
5-Year EBITDA Growth Rate: 11.10%
GF Value™: $19.19 vs. price of $18.10 (5.7% below fair value)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
82GF Score
Get the complete analysis for LUX:CIPLA
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
